ACTG 282

ACTG 282

• 批准号: 2353466
• 金额: --
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2353466
• 关键词: HIV infections; antiAIDS agent; antiviral agents; clinical trials; dosage; drug screening /evaluation; human immunodeficiency virus; human subject; human therapy evaluation; protease inhibitor

The purpose of this study is to determine the distribution of the Apolipoprotein E (APO-E) alleles in Alzheimer's disease (AD) patients and healthy elderly, the possible ethnic variations in the distribution of the APO-E alleles and to assess whether neuropathological and clinical variability and rate of decline in AD are accounted for by APO- E genotype. In addition we wish to establish a DNA bank for the testing of possible markers of AD. Since support was renewed in February 1996, collection of blood for the extraction of DNA from WBC's continued in all the live subjects participating in the Hopkins Alzheimer's Disease Research Center (ADRC). The remaining extracted DNA is stored for future studies. DNA from deceased subjects was extracted from frozen and fixed brain tissue. A total of 161 samples have been typed since funding was granted in June 1994. In the last funding period (12/l/95 through 11/30/96), a total of 23 participants have been genotyped. Of these 13 where women and 10 were men. Final results on prevalence of the Apo-E genotypes, racial differences and clinical and neuropathological correlations will be available in 1997 with completion of the typing of the entire cohort.

本研究的目的是确定 Alzheimer病患者载脂蛋白E等位基因的研究 和健康的老年人，可能的种族差异的分布， 的载脂蛋白E等位基因，并评估是否神经病理和 AD的临床变异性和下降率由APO- E基因型。 此外，我们希望建立一个DNA库， 可能的AD标志物 自从1996年2月恢复支助以来， 在所有活体受试者中继续从WBC中提取DNA 参与霍普金斯阿尔茨海默病研究中心（ADRC）。 剩下的DNA被保存起来，以备将来研究。 的DNA 从冷冻和固定的脑组织中提取死亡受试者。 一 自6月份获得资助以来，共对161个样本进行了分类 1994. 在上一个供资期间（1995年12月1日至1996年11月30日）， 的23名参与者进行了基因分型。 在这13个国家中， 都是男人 Apo-E基因型患病率的最终结果，人种 差异和临床和神经病理学的相关性将是 1997年完成了整个队列的定型工作。